Bladder cancer is the most common urinary tract malignancy, and 90% of bladder tumors are urothelial cell carcinomas. Ferroptosis is a new form of cell death discovered in recent years, which is an iron-dependent form of cell death characterized by the lethal intracellular accumulation of lipid-based reactive oxygen species.
Ashley Ross: So this is a patient who underwent a radical prostatectomy, about 18 months before presentation. At surgery, he had T3a disease, and he was Gleason grade group 3, 4 plus 3 equals 7. He had a positive surgical margin. Initially, his PSA was undetectable, but then it started to rise. And by the time […]
Daniel Spratt: I’m going to talk a little bit about the data supporting the addition of hormone therapy to postoperative radiation therapy. Really, we have two landmark published phase three randomized trials that have evaluated the benefit of hormonal therapy in this setting. Soon, we hope to see the results of a third randomized trial […]
Daniel Spratt: Hi, everyone. Thanks so much for being here and thanks so much to UroToday for sponsoring this session. I have two wonderful guests that are experts in the field of urologic and prostate cancer oncology. We have Dr. Ashley Ross, and also we have Dr. Allen Dal Pra, and I am Dan Spratt. […]
Lutetium-177-PSMA (LuPSMA) is a targeted systemic radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). LuPSMA is considered as an experimental treatment not yet used in routine practice.
Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy. To determine the local control (LC), progression-free survival (PFS), cumulative incidence of changing systemic therapy, and overall survival (OS) after SRT to oligoprogressive metastatic renal cell carcinoma (mRCC) lesions […]
Tyrosine kinase inhibitors (TKIs) have been widely used in the management of patients with metastatic renal cell carcinoma (RCC). However, the use of systemic therapies in the adjuvant setting of localized and locally advanced RCC has shown conflicting results across the literature.
With novel antiandrogen treatments of varying clinical benefits and risks becoming available, this study investigates how patients with castration-resistant prostate cancer (CRPC) value differences in treatment characteristics.
While multiple randomized trials have evaluated the benefit of radiation therapy (RT) dose escalation and the use and prolongation of androgen deprivation therapy (ADT) in the treatment of prostate cancer, few studies have evaluated the relative benefit of either form of treatment intensification with each other.
Despite the key importance of magnetic resonance imaging (MRI) parameters, risk classification systems for biochemical recurrence (BCR) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) are still based on clinical variables alone.
